Logo image of ORGN

ORIGIN MATERIALS INC (ORGN) Stock Fundamental Analysis

NASDAQ:ORGN - Nasdaq - US68622D1063 - Common Stock - Currency: USD

0.6  +0.03 (+5.26%)

Fundamental Rating

2

Taking everything into account, ORGN scores 2 out of 10 in our fundamental rating. ORGN was compared to 85 industry peers in the Chemicals industry. ORGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ORGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ORGN has reported negative net income.
In the past year ORGN has reported a negative cash flow from operations.
In multiple years ORGN reported negative net income over the last 5 years.
ORGN had a negative operating cash flow in each of the past 5 years.
ORGN Yearly Net Income VS EBIT VS OCF VS FCFORGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -27.57%, ORGN is doing worse than 87.06% of the companies in the same industry.
ORGN's Return On Equity of -30.59% is on the low side compared to the rest of the industry. ORGN is outperformed by 76.47% of its industry peers.
Industry RankSector Rank
ROA -27.57%
ROE -30.59%
ROIC N/A
ROA(3y)-0.36%
ROA(5y)-11.35%
ROE(3y)0.58%
ROE(5y)-6056.88%
ROIC(3y)N/A
ROIC(5y)N/A
ORGN Yearly ROA, ROE, ROICORGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

ORGN's Gross Margin of 1.31% is on the low side compared to the rest of the industry. ORGN is outperformed by 88.24% of its industry peers.
The Profit Margin and Operating Margin are not available for ORGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORGN Yearly Profit, Operating, Gross MarginsORGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

4

2. Health

2.1 Basic Checks

ORGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ORGN has more shares outstanding than it did 1 year ago.
ORGN has a worse debt/assets ratio than last year.
ORGN Yearly Shares OutstandingORGN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M
ORGN Yearly Total Debt VS Total AssetsORGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of 1.05, we must say that ORGN is in the distress zone and has some risk of bankruptcy.
ORGN has a Altman-Z score of 1.05. This is in the lower half of the industry: ORGN underperforms 78.82% of its industry peers.
ORGN has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ORGN's Debt to Equity ratio of 0.01 is amongst the best of the industry. ORGN outperforms 91.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1.05
ROIC/WACCN/A
WACC10.18%
ORGN Yearly LT Debt VS Equity VS FCFORGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 9.51 indicates that ORGN has no problem at all paying its short term obligations.
With an excellent Current ratio value of 9.51, ORGN belongs to the best of the industry, outperforming 98.82% of the companies in the same industry.
ORGN has a Quick Ratio of 9.44. This indicates that ORGN is financially healthy and has no problem in meeting its short term obligations.
ORGN has a better Quick ratio (9.44) than 98.82% of its industry peers.
Industry RankSector Rank
Current Ratio 9.51
Quick Ratio 9.44
ORGN Yearly Current Assets VS Current LiabilitesORGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ORGN have decreased strongly by -4035225266123964928.00% in the last year.
Looking at the last year, ORGN shows a very negative growth in Revenue. The Revenue has decreased by -11.91% in the last year.
EPS 1Y (TTM)-4035225266123965000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)-11.91%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-20.44%

3.2 Future

Based on estimates for the next years, ORGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.99% on average per year.
Based on estimates for the next years, ORGN will show a very strong growth in Revenue. The Revenue will grow by 87.52% on average per year.
EPS Next Y10.75%
EPS Next 2Y15.81%
EPS Next 3Y17.39%
EPS Next 5Y16.99%
Revenue Next Year46.92%
Revenue Next 2Y89.65%
Revenue Next 3Y96.88%
Revenue Next 5Y87.52%

3.3 Evolution

ORGN Yearly Revenue VS EstimatesORGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
ORGN Yearly EPS VS EstimatesORGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ORGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ORGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORGN Price Earnings VS Forward Price EarningsORGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORGN Per share dataORGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

ORGN's earnings are expected to grow with 17.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.81%
EPS Next 3Y17.39%

More info and screens

0

5. Dividend

5.1 Amount

ORGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORIGIN MATERIALS INC

NASDAQ:ORGN (7/17/2025, 2:49:27 PM)

0.6

+0.03 (+5.26%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners15.29%
Inst Owner Change0%
Ins Owners4.47%
Ins Owner Change10.5%
Market Cap89.96M
Analysts82.86
Price Target2.04 (240%)
Short Float %2.52%
Short Ratio3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-38.15%
Min EPS beat(2)-96.08%
Max EPS beat(2)19.79%
EPS beat(4)1
Avg EPS beat(4)-31.09%
Min EPS beat(4)-96.08%
Max EPS beat(4)19.79%
EPS beat(8)5
Avg EPS beat(8)32.19%
EPS beat(12)9
Avg EPS beat(12)116.34%
EPS beat(16)13
Avg EPS beat(16)141.29%
Revenue beat(2)0
Avg Revenue beat(2)-41.07%
Min Revenue beat(2)-81.71%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-2%
Min Revenue beat(4)-81.71%
Max Revenue beat(4)77.24%
Revenue beat(8)3
Avg Revenue beat(8)-6.89%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)60%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.01
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.2
BVpS2.1
TBVpS2.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.57%
ROE -30.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.31%
FCFM N/A
ROA(3y)-0.36%
ROA(5y)-11.35%
ROE(3y)0.58%
ROE(5y)-6056.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 127.73%
Cap/Sales 46.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.51
Quick Ratio 9.44
Altman-Z 1.05
F-Score3
WACC10.18%
ROIC/WACCN/A
Cap/Depr(3y)4824.97%
Cap/Depr(5y)3442.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4035225266123965000%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y10.75%
EPS Next 2Y15.81%
EPS Next 3Y17.39%
EPS Next 5Y16.99%
Revenue 1Y (TTM)-11.91%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-20.44%
Revenue Next Year46.92%
Revenue Next 2Y89.65%
Revenue Next 3Y96.88%
Revenue Next 5Y87.52%
EBIT growth 1Y-11.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.46%
EBIT Next 3Y14.85%
EBIT Next 5Y43.23%
FCF growth 1Y64.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.05%
OCF growth 3YN/A
OCF growth 5YN/A